rs34637584, LRRK2

N. diseases: 78
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. 20818610 2010
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE There was no increased association between G2019S or R1441G mutations and any type of cancer. 24357540 2014
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. 25401981 2015
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). 31348549 2019
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE Furthermore, the aberrant neural pluripotency is consistent with Parkinson's pathophysiology and with the epidemiological association between the G2019S genotype and cancer risk. 31373835 2020